Vanguard Group Inc Nuvalent, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,776,016 shares of NUVL stock, worth $334 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,776,016
Previous 3,412,072
10.67%
Holding current value
$334 Million
Previous $256 Million
11.8%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding NUVL
# of Institutions
178Shares Held
56.5MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.77 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$405 Million14.04% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$268 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$239 Million41.86% of portfolio
-
Perceptive Advisors LLC New York, NY2.55MShares$226 Million5.59% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.8B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...